Is montelukast effective in regression of endometrial implants in an experimentally induced endometriosis model in rats?

Şadıman Kıykaç Altınbaş, Sadiman Kiykac Altinbas, Omer Lutfi Tapisiz, Ömer Lütfi Tapısız, Cavkaytar S, Sabri Cavkaytar, Simsek G, Gülçin Şımşek, Gulcin Simsek, Oguztuzun S, Serpil Oguztuzun, Serpil Oğuztüzün, Goktolga U, Umit Goktolga, Ümit Göktolga
European journal of obstetrics, gynecology, and reproductive biology · 2014 · vol. 184 , pp. 7–12 · doi:10.1016/j.ejogrb.2014.10.026 · PMID:25462212 · W2014770933
Lab / animal OA: closed CC0 ⤵ 8 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

This study investigated whether montelukast could regress experimentally induced endometriosis implants in a rat model.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

OBJECTIVE: Montelukast, a selective antagonist of Type 1 cysteinyl leukotriene receptors (CysLT1Rs), antagonizes the proinflammatory and proasthmatic activities of CysLT1Rs. We investigated the effect of montelukast on a surgically induced endometriosis rat model. STUDY DESIGN: Thirty-two sexually mature, cycling, female Wistar-Albino rats, in which endometriotic implants were surgically induced, were randomly divided into three groups. Group I [Montelukast (M), 10 rats)] was given 1.6 mg/kg/day of oral montelukast sodium. Group II [Leuprolide acetate (L), 11 rats] was given 1 mg/kg single dose of s.c.leuprolide acetate. Group III [Control (C), 11 rats] received saline solution through an orogastric tube and served as controls. After a 3-weeks medication, the rats were sacrificed to investigate the endometriotic implants for size and morphological and histological characteristics, including immunoreactivity of MMP-2 and VEGF. RESULTS: The mean area of implants decreased from 48.2 ± 24.7 to 29.3 ± 15.8mm(2) in Group I (M) (P = 0.008) and from 62 ± 32.1 to 39.9 ± 18.1mm(2) in Group II (L) (P=0.003). In Group III (C), the mean area increased from 41.1 ± 31.1 to 60.4 ± 37.1mm(2) (P = 0.025). Histopathological analysis showed statistically significant lower scores in rats treated with montelukast compared to leuprolide and controls. MMP H scores were not different between the groups in both epithelial and stromal MMP-2 immunostaining. VEGF H scores were statistically lower in Group 1 (M) in epithelial VEGF immunostaining when compared to Group II (L) and Group III (C) (P=0.006). CONCLUSION(S): Montelukast may effectively cause a significant decrease in the area of endometriotic implants.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Acetates Anti-Inflammatory Agents Endometriosis Endometrium Quinolines Acetates Acetates Acetates Animals Animals Anti-Inflammatory Agents Anti-Inflammatory Agents Anti-Inflammatory Agents Cyclopropanes Cyclopropanes Disease Models, Animal Disease Models, Animal Endometriosis Endometriosis Endometriosis

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (32)

Cited by (8)

Source provenance

europepmc
last seen: 2026-10-15T06:08:49.021275+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:14:41.184593+00:00
unpaywall
last seen: 2026-10-15T06:24:24.424788+00:00
License: CC0 · commercial use OK